Supernus Pharma (NASDAQ: SUPN) reported Q4 EPS of ($0.07), $0.48 worse than the analyst estimate of $0.41. Revenue for the quarter came in at $211.6 million versus the consensus estimate of $195.48 million.

GUIDANCE:

Supernus Pharma sees FY2026 revenue of $840-870 million, versus the consensus of $861.2 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.